SCHEMBL10259134

SCHEMBL10259134

C=C(I)/C=C\c1ccc(C)cc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 1/20 0.47
▸ CYP1B1 Q16678 1/20 0.47
▸ TDP1 Q9NUW8 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ MAPT P10636 3/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ AMY1A P0DUB6 1/20 0.40
▸ TP53 P04637 1/20 0.38
▸ ALOX5 P09917 1/20 0.35
▸ PTGS1 P23219 1/20 0.35
▸ PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21162500 0.81 CYP1A1 (0.47) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL16170090 0.77 CYP1A1 (0.43) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL11323718 0.77 AMY1A (0.47) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL6546420 0.77 AMY1A (0.47) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL13816225 0.77 TSHR (0.43) LMNAMAPTMEN1KMT2AKDM4E
SCHEMBL14303656 0.76 CYP1A1 (0.55) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL2865211 0.76 CYP1A1 (0.55) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL31356822 0.76 CYP1A1 (0.55) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL584565 0.76 CYP1A1 (0.55) CYP1A1CYP1B1TDP1LMNAMAPT
SCHEMBL584566 0.76 CYP1A1 (0.55) CYP1A1CYP1B1TDP1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012036253-A1 HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-22 — — WO disclosed
Send feedback